Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034063 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL817047 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL346766 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL11326603 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL21352704 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL21352709 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL9244114 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL9329621 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL196188 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL490162 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103657518-B | A kind of Nonionic organosilicon surfactant and preparation method thereof | NANJING MAYSTA CHEMICAL CO., LTD. (CN) | 2015-11-04 | — | — | CN | claimed |
| CN-103657518-A | Nonionic organosilicon surfactant and preparation method thereof | NANJING MAYSTA NEW MATERIALS CO LTD | 2014-03-26 | — | — | CN | claimed |
| CN-103638872-A | Trisiloxane polyether-ester surfactant as well as preparation method thereof | NANJING MEISIDE NEW MATERIALS CO LTD | 2014-03-19 | — | — | CN | claimed |
| US-7479531-B2 | Copolymer of ethylene and/or propylene; and octen-1-ol,7-octen-1-ol trimethylsilyl ether, octenyl acetate, 5-norbornen-2-yl acetate, 5-norbornen-2-ol and/or 5-norbornen-2-ol trimethylsilyl ether; transition metal catalyst comprising 2-arylazo- or 2-arylphosphazo- phenoxide ligand | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-01-20 | — | — | US | claimed |
| US-7285609-B2 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-23 | — | — | US | claimed |
| EP-1626999-B1 | OLEFIN POLYMERIZATION CATALYST SYSTEM USEFUL FOR POLAR MONOMERS | EXXONMOBIL CHEM PATENTS INC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070197751-A1 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-08-23 | — | — | US | claimed |
| EP-1626999-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM USEFUL FOR POLAR MONOMERS | Exxonmobil Chemical Patents Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| US-20040260043-A1 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS, INC. | 2004-12-23 | — | — | US | claimed |
| WO-2004101634-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM USEFUL FOR POLAR MONOMERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-11-25 | — | — | WO | claimed |
| US-20260115139-A1 | Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NANOVATION THERAPEUTICS INC. (CA) | 2026-04-30 | — | — | US | disclosed |
| US-20260102347-A1 | Sulfur-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NANOVATION THERAPEUTICS INC. (CA) | 2026-04-16 | — | — | US | disclosed |
| EP-4711518-A1 | COATED FIBERS AND MOLDED BODY USING SAME | Kuraray Co., Ltd. (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4667451-A1 | PESTICIDALLY-ACTIVE 2,2-DIHALOCYCLOPROPYL COMPOUNDS | Syngenta Crop Protection AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-12460111-B2 | Reinforcing fibers and production method therefor, and molded article using same | KURARAY CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| US-20040122192-A1 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20020156207-A1 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2002-10-24 | — | — | US | disclosed |
| EP-1186619-A2 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition contaning the copolymer, and uses thereof | Mitsui Chemicals, Inc. (JP) | 2002-03-13 | — | — | EP | disclosed |
| EP-0956047-A1 | NEW CARRIER SYSTEMS | IPR-Institute for Pharmaceutical Research Riehen AG (CH) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998016251-A1 | NEW CARRIER SYSTEMS | IPR-INSTITUTE FOR PHARMACEUTICAL RESEARCH AG (CH) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115139-A1 | Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | SLC43A1, SLC7A1, SLC7A5 | LMNA 556/4885ALDH1A1 2734/4885MAPT 3548/4885 |
| US-20260102347-A1 | Sulfur-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NSUN2, SGMS2, SGMS1 | LMNA 717/4885ALDH1A1 3276/4885MAPT 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.